This site is intended for U.S. Health Care Professionals
Oncology News features editorially independent news content provided by MDLinx. Pfizer does not influence and is not involved with the selection of content in this section.
| Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer von Minckwitz G et al. The addition of bevacizumab to neoadjuvant chemotherapy significantly incr.. | Fri, 27 Jan 2012 | |
| Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomized controlled trial Bang YJ et al. Adjuvant capecitabine plus oxaliplatin treatment after curative D2 gastrectomy sho.. | Fri, 27 Jan 2012 | |
| A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: Development and international validation studies Kratz JR et al. The frequent recurrence of early-stage non-small-cell lung cancer (NSCLC) is gene.. | Fri, 27 Jan 2012 | |
| Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy Cao MD et al. The differences in tumor metabolic response to NAC were associated with breast can.. | Fri, 27 Jan 2012 | |
| Identification of a biomarker panel for colorectal cancer diagnosis Garcia-Bilbao A et al. The authors have developed a tentative model for the diagnosis of colorect.. | Fri, 27 Jan 2012 | |
Click here to view more articles.
The article you selected will open in a new window, and you will be redirected to the publisher's web site. To return to Pfizer for Oncology Professionals, close the new window.
